Objective: Circulating endothelial progenitor cells (EPCs), responsible for neoangiogenesis and vascular repair, negatively correlate with vascular dysfunction and atherosclerotic risk factors. Because obesity may have a crucial role in the development of endothelial dysfunction, this study evaluated the number and proliferative activity of circulating human EPCs in obese (body mass index (BMI) ¼ 48±9, n ¼ 45) compared with lean (23±2, n ¼ 45) volunteers. Methods: EPCs were quantified after isolation of peripheral blood mononuclear cells (PBMCs) using fluorescence-activated cell sorting analyses. In addition, plated PBMCs developed colony-forming units (CFUs) from which 'outgrowth' endothelial cells (OECs) sprouted and differentiated into mature endothelial cells. Growth rates were monitored by periodical microscopic evaluation. Cell-cycle protein expression was determined by western blot analyses. Results: BMI negatively correlated (Po0.01) with the number of CD34
Introduction
Obesity, defined by a body mass index (BMI) of at least 30 kg m
À2
, is a widespread disease of increasing prevalence 1 and may have a crucial role in the development of endothelial dysfunction, 2 which precedes manifest vascular disease. Not only could adipose-tissue-derived mediators add to vascular dysfunction 2 but also obesity is associated with a number of comorbidities, including hypertension, hyperlipidemia, systemic inflammation and overt diabetes, all of which could trigger endothelial dysfunction. [2] [3] [4] Endothelial cell loss through damage/apoptosis induced by atherogenic risk factors 5, 6 requires replenishment of endothelial cells in the vessel wall. In this process, two mechanisms are likely to be responsible for postnatal vasculogenesis in physiological and pathophysiological neovascularization: (1) an increased mitotic response and turnover of nearby located endothelial cells and/or (2) reendothelialization by the attachment of endothelial progenitor cells (EPCs). 7 This cell type was first identified about a decade ago, 8 has been shown to circulate in human peripheral blood and expresses both progenitor and endothelial marker proteins. On attachment to the site of injured endothelium, EPCs differentiate into mature endothelial cellsFthe latter exclusively showing classical endothelial morphology and characteristicsFand thereby maintain the integrity of the endothelial monolayer. 8, 9 The negative correlation of EPCs with numerous atherosclerotic risk factors 10, 11 indicates the importance of this cell type in vascular dysfunction, although only limited data are available on the number of EPCs in obese patients. In this context, circulating EPCs have recently been shown to be reduced in obese men with metabolic syndrome compared with lean men without metabolic syndrome. 12 Moreover, weight loss has been shown to contribute to an increase in EPC numbers during participation of the respective individuals in a diet program. 13 However, these reports primarily focus on the CD34 þ /KDR þ subtype of EPCs, 12, 13 whereas only limited information is available on early EPC subtypes such as CD34 þ /KDR þ /CD133 þ 14 and CD133 þ /KDR þ EPCs in obesity. In addition, the effect of obesity on the proliferative activity of 'outgrowth' endothelial cells (OECs, differentiated from cultured EPCs) has not yet been investigated. This study therefore evaluated the hypotheses that the number and proliferative activity of EPCs are reduced in obesity. To this end, we (1) determined the number of EPCs, defined as cells coexpressing at least one stem-(CD133) or progenitor cell marker (CD34), in combination with the typical endothelial antigen KDR (VEGFR-2), (2) quantified the formation of colonies (colony-forming units, CFUs) growing out from seeded peripheral blood mononuclear cells (PBMCs) in lean compared with obese (class II-III) subjects, (3) assessed in detail the relation between EPCs/ CFUs and numerous metabolic parameters that are regarded as obesity-related risk factors in vascular disease and (4) evaluated the proliferative activity of OECs, including the expression of cell-cycle proteins as cyclins, cyclin-dependent kinases (CKIs) and their inhibitors, transcription factor E2F-1 and retinoblastoma protein (pRb).
Materials and methods

Reagents
Triton X-100, Nonidet P-40, Na 3 VO 4 , b-glycerophosphate, phenylmethylsulfonyl fluoride, aprotinine, leupeptin, Ponceau S, Histopaque 1077, Medium 199 and fibronectin were purchased from Sigma Chemical Co (St Louis, MO, USA). Phosphate-buffered saline (PBS), L-glutamine, fetal calf serum and antibiotics were from Hyclone (Logan, UT, USA). Heparin was from Biochrom (Berlin, Germany). EDTA, NaCl, NaN 3 , MgCl 2 , NaOH, NaHCO 3 , Tris and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid were from Merck (Darmstadt, Germany ; Sarstedt, Wr Neudorf, Austria) in Medium 199 supplemented with 20% fetal calf serum, 5 U ml À1 heparin, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and 500 ng ml À1 fungizone. 5 Briefly, after 2 days of 'pre-adsorption' of contaminating early-attaching mesenchymal cells, nonattached cells were replated on dishes with a grid at their bottom to allow for an absolute quantification of CFUs. The total amount of CFUs was quantified by counting all colonies per plate on day 5 after the replating procedure by two independent investigators in a blinded manner ( Figure 1c ). The number of CFUs was then normalized on the lymphocyte population, which was determined in parallel during FACS analyses (see above). On further cultivation, OECs grew out from these CFUs and differentiated into endothelial cells (Figures 1d and e) of 490% purity, as characterized by negative staining for the monocyte marker CD14 (Figure 1f ), but expression of the endothelial marker proteins endocan (ESM-1) (Figure 1g ), as well as CD31 (platelet-endothelial cell adhesion molecule-1, PECAM-1) and CD144 (vascular endothelial-cadherin, VE-Cadherin) (Figures 1h and i) .
Flow cytometric analysis of PCNA After 3 weeks of culture, OECs were scraped off the dishes and fixed in ice-cold ethanol (75%). Proliferating cells as characterized by positive staining of proliferation cellular nuclear antigen (PCNA) were quantified using a FACSCalibur (Becton Dickinson).
Western blot analyses
Outgrowth endothelial cells from obese and lean subjects (n ¼ 24 for each group), matched for age, gender, diabetes and smoking, were cultured for 3 weeks. The cells were then rinsed with cold PBS and lysed in cold Weinberg buffer
sulfonyl fluoride, 2 mmo l À1 benzamidine, 10 mg ml À1 aprotinine, 10 mg ml À1 leupeptin) and subjected to a freeze-thaw cycle. After removing cellular debris by centrifugation (15 000 g, 10 min, 4 1C), aliquots of the supernatant, containing 10 mg of total protein (measured by bicinchoninic acid protein assay according the manufacturer's instructions), were subjected to SDS-polyacrylamide gel electrophoresis and subsequently transferred onto nitrocellulose membranes (Schleicher and Schüll, Kassel, Germany). After controlling for homogenous sample loading by staining the blots with Ponceau S, blocking of unspecific binding sites with non-fat dry milk (5% in Tris buffered saline containing 0.05% Tween 20) was followed by incubation with primary antibodies (cyclins B and D3, as well as p21 WAFÀ1/Cip1 (1:500), cyclins E and A, as well as E2F-1 (1:200), cdk-2 and p27 Kip (1:1000), pRb (1:50)), which were detected with horseradish-peroxidase-conjugated anti-mouse IgG (1:2500) using Super Signal Substrate. Western blots were exposed to Kodak XAR5-Omat films and semiquantitative evaluation of visualized bands was carried out by densitometry (Gel documentation system; MWG Biotech, Ebersberg, Germany) using Gene Profiler 3.56 for Windows (Scanlytics Inc., Fairfax, VA, USA). Protein expression is depicted in arbitrary units.
Statistics
Patient characteristics are expressed as means ± s.d. and comparisons between groups were analyzed by independent r=-0.500** t test: * Figure 2 Reduction of endothelial progenitor cells (EPCs) in obesity. BMI strictly correlates with reduction of CD34 Endothelial
Relation of endothelial progenitor cells to obesity-associated risk factors
The hormone leptin, elevated in obese people, negatively correlated with all subsets of freshly isolated EPCs, that is, Total cholesterol, LDL, ApoB, lipoprotein (a) and plasma free fatty acids, commonly regarded as atherogenic risk factors, were not different between lean and obese subjects, nor were there any correlations between these parameters and the number of EPCs or CFUs (data not shown). This also relates to triglycerides, which did not affect EPC numbers even though triglyceride levels were elevated in obesity.
EPC proliferation and associated protein expression As monitored by periodical microscopic evaluation, growth rates of cultured OECs differentiated from EPCs of obese subjects were clearly retarded compared with those of the lean control group (obese: 19.9±2.2% vs lean: 30.9±3.2% grown area per week, n ¼ 45 for each group, Po0.01). This observation was confirmed by reduced protein expression of PCNA in obese compared with OECs of lean subjects in a limited number of experiments (obese: 40.5 ± 8.6% vs lean: 74.4 ± 6.0% PCNA-positive cells, n ¼ 15 for each group, Po0.01).
Therefore, systematic analyses of cell-cycle proteins were performed. In OECs from obese volunteers (n ¼ 24), protein expression of cyclin D3 (G 1 phase cyclin), cyclin E (G 1 -S transition), cyclin A (S-phase cyclin) and cyclin B (G 2 -M phase), as well as that of the transcription factor E2F-1, was downregulated compared with that in lean controls (n ¼ 24, Figures 7a and b) , whereas CKI cdk-2 (data not shown), forming active complexes with cyclins D3, E and A, was not affected. In addition, protein expression of the inhibitor of CKI p27
Kip remained unaffected (data not shown), whereas that of p21 WAFÀ1/Cip1 (another CKI) was upregulated in the obese study group (Figures 7a and b) . Moreover, preliminary results (n ¼ 10 for each group) indicated that the expression and hyperphosphorylation of pRb were markedly reduced in OECs derived from obese subjects (Figure 7b ).
Discussion
This study provides evidence that obesity decreases the number of circulating EPCs (defined as CD34
and the proliferative capacity of OECs, differentiated from PBMCs. This observation supports the contention of a detrimental and/or retarding potential of obesity itself and/or of obesity-related risk factors on EPCsFa cell type with the potential to home at sites of endothelial injury and regarded as responsible for maintenance of endothelial integrity. Thereby, the results of our study extend reports of reduced CD34 þ /KDR þ EPCs (1) in obese men with metabolic syndrome compared with lean and healthy controls 12 and (2) in participants of a weight loss study before and after their attendance at a diet program, 13 as well as (3) of a decreased number of CD45
þ EPCs in a small study group of obese adults.
14 Although the number of all subsets of EPCsFdefined as cells coexpressing CD133 and/or CD34 in combination with the endothelial surface marker KDRFnegatively correlates with BMI, CPCs (defined as CD34 þ /CD133 þ double-positive cells) are not affected by obesity (data not shown). The latter finding is, however, in contrast to one of the previous studies reporting reduced numbers of CD34 þ /CD133 þ CPCs with increasing BMI, 13 although the reason for this discrepancy remains elusive. Several metabolic parameters that are regarded as atherosclerotic risk factors, such as cholesterol, LDL, ApoB, lipoprotein (a) and plasma free fatty acids, are not different between lean and obese subjects. Interestingly, the obesityinduced reduction of circulating EPCs occurs independently of these risk factors. Moreover, although triglyceride levels are found to be elevated in obese patients, no correlation could be found between EPC numbers and triglycerides. To Endothelial progenitor cells in obesity K Tobler et al the best of our knowledge, the relation of circulating EPCs to ApoB, lipoprotein (a) and plasma free fatty acids has not been previously studied in detail. However, in accordance with our data, cholesterol [14] [15] [16] and triglycerides 14, 16 were already described to be ineffective on CD34 þ /KDR þ and
þ EPCs, whereas heterogeneous results were found on the effects of LDL on EPC numbers. 14, 16, 17 Although there are several reports on reduced EPCs in diabetes, 15, 16 little attention has been paid to a direct association between EPCs and glycosylated hemoglobin. This study shows that HbA 1c plasma concentrations strictly correlate with BMI and that nearly 30% of obese patients had at least slightly elevated HbA 1c levels. Moreover, we found CD34 þ EPCs to be markedly reduced with increasing glycosylation of hemoglobin. The same relates to hyperinsulinemia, hsCRP and hypertension, all of which are found to be strongly associated with obesity and, collaterally, to give rise to reduced CD34 þ EPCs. Considering methodologically comparable reports, even these wellknown obesity-related risk factors have not been studied extensively regarding their actions on EPCs. So far, the investigation of EPC number in relation to hsCRP or hypertension led to heterogeneous results. [14] [15] [16] [18] [19] [20] However, for determination of extremely rare eventsFas is the case in EPC analysisFa very high number of PBMCs must be analyzed to obtain reliable results. As an aside, we had the possibility to evaluate about 30-50 times more events in this study compared with most of the previous reports. Although CFUs poorly mirror circulating numbers of EPCs, they have been assumed to reflect the ability of EPCs to proliferate. 31 By daily documented microscopic monitoring of the plated PBMCs, we noticed that the outgrowing cells of the obese group showed delayed proliferation compared with those of the lean group. These findings were confirmed in pilot experiments using the general proliferation marker PCNA and led us to a subsequent detailed evaluation of cell-cycle proteins. Proliferation is driven by binding of cyclins (periodically synthesized cell-cycle proteins) to CKIs (cdks). These activated, that is, 'cyclin-bound', cdks subsequently phosphorylate pRb, which in its unphosphorylated form sequestrates the transcription factor E2F-1. Owing to its phosphorylation, pRb changes its conformation and liberates E2F-1, which in its free form induces transcription of cyclins and several DNA replication enzymes and thereby promotes cell-cycle progression. 32 Whereas cdk-2 (forming complexes with cyclins D3, E and A) remains unaffected, all of the tested cyclins are downregulated in EPCs isolated from obese volunteers compared with lean controls even after 3 weeks of culture. Therefore, the lower expression levels of cyclins could, at least in part, account for the reduced activity of cyclin-cdk complexes. The activities of these complexes, however, not only depend on the expression levels of their subunits but are additionally controlled by cdk inhibitors such as p27 Kip 34 Consequently, E2F-1 deficiencyFas also found in obesity in this studyFultimately leads to the observed growth arrest. Considering that the delay in proliferation persists for at least 3 weeks from cell isolation, combined with the determined protein expression pattern, the OECs from obese volunteers are presumably subject to an irreversible senescent-like growth arrest rather than to reversible quiescent-like growth retardation. This assumption is corroborated by the finding that p27 Kip usually accumulates in quiescence, but again declines during senescence, 35 thus explaining the lack of p27 Kip upregulation in obesity. Indeed, hypertension as well as hsCRP was already described to contribute to human EPC senescence, 36,37 whereas atheroprotective HDL was found to slow down EPC senescence. 38 Finally, this study provides several advantages over previous work. First, we acquired an extremely large number of cells to ensure reliable quantification of rare events. Second, we chose FACS analyses as an objective, sensitive, specific and reproducible method to minimize biases. Figure 2 ). It is, however, not yet clear which parameters compensate for EPC loss through risk factor accumulation and thus lead to the maintenance of surprisingly high amounts of EPCs in obesity. Conclusively, reduced numbers of EPCs along with their premature senescence, as shown in this study, could function as early contributors to the development and progression of vascular dysfunction in obese patients.
